Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | UBE2N | P61088 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 2/20 | 0.40 |
| ▸ | F9 | P00740 | 3/20 | 0.39 |
| ▸ | F11 | P03951 | 2/20 | 0.39 |
| ▸ | F7 | P08709 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | USP7 | Q93009 | 1/20 | 0.38 |
| ▸ | ADK | P55263 | 2/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.37 |
| ▸ | SENP1 | Q9P0U3 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19479287 | 0.78 | KMT2A (0.44) | MEN1KMT2AALDH1A1KDM4EHPGD | |
| SCHEMBL1001064 | 0.77 | ALOX15 (0.40) | MEN1KMT2AALDH1A1MAPK1ADK | |
| SCHEMBL4070584 | 0.77 | KMO (0.42) | MEN1KMT2AKDM4EUSP7ADK | |
| SCHEMBL3164324 | 0.76 | BCL2L1 (0.40) | ALDH1A1HPGDMAPK1HSD17B10ALOX5 | |
| SCHEMBL7812578 | 0.74 | ALOX5 (0.39) | MEN1KMT2AALDH1A1KDM4EACHE | |
| SCHEMBL4065247 | 0.73 | ADK (0.44) | MEN1KMT2AALDH1A1KDM4EHPGD | |
| SCHEMBL5763304 | 0.72 | MEN1 (0.47) | MEN1KMT2AALDH1A1KDM4EUSP7 | |
| SCHEMBL7015277 | 0.71 | RPS6KA3 (0.44) | MEN1KMT2AALDH1A1KDM4EHPGD | |
| SCHEMBL7818543 | 0.71 | CYP1A2 (0.46) | MEN1KMT2AMAPK1NPSR1ACHE | |
| SCHEMBL21385864 | 0.71 | ACHE (0.61) | ALDH1A1HPGDTSHRHSD17B10ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1322624-B1 | ARYLALKANE-SULFONAMIDES HAVING ENDOTHELIN-ANTAGONIST ACTIVITY | ACTELION PHARMACEUTICALS LTD (CH) | 2009-10-21 | — | — | EP | disclosed |
| CN-100537546-C | Novel alkansulfonamides as endothelin antagonists | ACTELION PHARMACEUTICALS LTD (CH) | 2009-09-09 | — | — | CN | disclosed |
| CN-100432070-C | Novel sulfamides and their use as endothelin receptor antagonists | ACTELION PHARMACEUTICALS LTD (CH) | 2008-11-12 | — | — | CN | disclosed |
| US-7323465-B2 | Alkansulfonamides as endothelin antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2008-01-29 | — | — | US | disclosed |
| US-7323465-B2 | Alkansulfonamides as endothelin antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2008-01-29 | — | — | US | disclosed |
| US-7323465-B2 | Alkansulfonamides as endothelin antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2008-01-29 | — | — | US | disclosed |
| EP-1465875-B1 | NOVEL ALKANSULFONAMIDES AS ENDOTHELIN ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2007-12-19 | — | — | EP | disclosed |
| EP-1465875-B1 | NOVEL ALKANSULFONAMIDES AS ENDOTHELIN ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2007-12-19 | — | — | EP | disclosed |
| US-7285549-B2 | Sulfamides and their use as endothelin receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2007-10-23 | — | — | US | disclosed |
| CN-1326841-C | Arylalkane-sulfonamides having endothelin antagonist activity | ACTELION PHARMACEUTICALS LTD (CH) | 2007-07-18 | — | — | CN | disclosed |
| US-20030087920-A1 | Butyne diol derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2003-05-08 | — | — | US | disclosed |
| WO-2002083650-A1 | NOVEL SULFONYLAMINO-PYRIMIDINES | ACTELION PHARMACEUTICALS LTD (CH) | 2002-10-24 | — | — | WO | disclosed |
| EP-1244637-A1 | BUTYNE DIOL DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2002-10-02 | — | — | EP | disclosed |
| WO-2002053557-A1 | NOVEL SULFAMIDES AND THEIR USE AS ENDOTHELIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2002-07-11 | — | — | WO | disclosed |
| WO-2002024665-A1 | ARYLALKANE-SULFONAMIDES HAVING ENDOTHELIN-ANTAGONIST ACTIVITY | ACTELION PHARMACEUTICALS LTD (CH) | 2002-03-28 | — | — | WO | disclosed |
| WO-2002008200-A2 | ARYLETHENE-SULFONAMIDES, THEIR PREPARATION AND THEIR USE AS ENDOTHELIN ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2002-01-31 | — | — | WO | disclosed |
| WO-2001081335-A1 | PYRIMIDINE-SULFONAMIDES HAVING ENDOTHELIN-ANTAGONIST ACTIVITY | ACTELION PHARMACEUTICALS LTD (CH) | 2001-11-01 | — | — | WO | disclosed |
| EP-1137642-A1 | BIS-SULFONAMIDES | Actelion Pharmaceuticals Ltd. (CH) | 2001-10-04 | — | — | EP | disclosed |
| WO-2001046156-A1 | BUTYNE DIOL DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2001-06-28 | — | — | WO | disclosed |
| WO-2001017976-A1 | BIS-SULFONAMIDES | ACTELION PHARMACEUTICALS LTD (CH) | 2001-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087920-A1 | Butyne diol derivatives | BDKRB2, EDNRB, EDNRA | MEN1 1644/4885KMT2A 4818/4885ALDH1A1 691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.